NASDAQ : SLN

Silence Therapeutics plc — Company profile

Healthcare · Biotechnology · United Kingdom

Last price 19.75 USD (Oct 30, 2026, 3:17 PM EDT) · Market cap 1.19B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom.

Details

NameSilence Therapeutics plc
SectorHealthcare
IndustryBiotechnology
Employees88
Founded1994
CeoIain Ross
CountryUnited Kingdom
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
IsinUS82686Q1013
Cusip82686Q101
Cik1479615
Sic2834

Key executives

NameTitle
Iain Gladstone Ross B.Sc., BSc (Hons), C.DIR, CH.DInterim Chief Executive Officer and Chairman of the Board
Rhonda L. HellumsExecutive Vice President, Chief Financial Officer, Secretary and Executive Director
Dr. Steven J. Romano M.D.Executive Vice President and Chief Research and Development Officer
Dr. Marie Wikstrom Lindholm Ph.D.Chief Scientific Officer
Jaimin B. ShahSVice President and General Counsel
J.P. GabrielChief Technical Operations Officer
Curtis Rambaran M.D.Chief Medical Officer

Contact

Address12 Hammersmith Grove, London, W6 7AP, United Kingdom
Phone44 20 3457 6900
Websitehttps://www.silence-therapeutics.com